Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical ...

India's contract drug makers have urged the government to remove regulatory hurdles and grant faster clearance to vital raw ...

India's contract drug makers have urged the government to remove regulatory hurdles and grant faster clearance to vital raw ...

India's CRDMO sector is projected to reach US$ 25 billion by 2035, driven by cost advantages, fast project startups, and growing biologics expertise, strengthening its global pharma innovation role.

India currently holds a 2-3 per cent share of the USD 140-145 billion global CRDMO market but has the potential to become a ...

India's CRDMO sector is poised for significant growth, with potential to reach USD 25 billion by 2035, driven by de-risking ...

India’s CRDMO market, currently holding 2-3% of the global share, has the potential to reach $22-25 billion by 2035, says a ...

This surge is also being driven by India's cost advantages compared to Western countries, 90 per cent faster project startup ...

Hyderabad: The Contract Research, Development, and Manufacturing Organisation (CRDMO) sector in India is at an inflection ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's ...

The Indian Contract Research, Development, and Manufacturing Organization (CRDMO) sector is expected to touch USD 22 billion ...